FAES FARMA, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.285 EUR | +3.30% |
|
+4.78% | +3.96% |
| Feb. 27 | FAES FARMA : Q4 profitability exceeded expectations |  |
| Feb. 27 | Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 476M 510M | Sales 2025 * | 496M 532M | Capitalization | 1.02B 1.1B |
|---|---|---|---|---|---|
| Net income 2024 * | 89M 95.34M | Net income 2025 * | 91M 97.48M | EV / Sales 2024 * | 2.17 x |
| Net Debt 2024 * | 9.8M 10.5M | Net cash position 2025 * | 64.45M 69.04M | EV / Sales 2025 * | 1.93 x |
| P/E ratio 2024 * |
11.3
x | P/E ratio 2025 * |
11.1
x | Employees | 1,748 |
| Yield 2024 * |
4.72% | Yield 2025 * |
4.79% | Free-Float | 91.13% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +3.30% | ||
| 1 week | +4.78% | ||
| Current month | +4.45% | ||
| 1 month | +4.12% | ||
| 3 months | +5.80% | ||
| 6 months | +12.12% | ||
| Current year | +3.96% |
1 week
3.14
3.30
1 month
3.063.30
Current year
2.913.30
1 year
2.873.44
3 years
2.874.29
5 years
2.875.48
10 years
1.615.48
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Chief Executive Officer | - | - | |
| Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 18-06-18 | |
| Chairman | - | 91-05-15 | |
| Director/Board Member | - | 94-06-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 3.285 | +3.30% | 435,056 |
| 24-04-22 | 3.18 | -0.16% | 197,605 |
| 24-04-19 | 3.185 | +0.31% | 151,128 |
| 24-04-18 | 3.175 | +0.95% | 150,305 |
| 24-04-17 | 3.145 | +0.32% | 123,431 |
Delayed Quote BME, April 23, 2024 at 11:35 am EDT
More quotes
Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Companyâs research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
3.285
EUR
Average target price
3.708
EUR
Spread / Average Target
+12.86%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.96% | 1.05B | |
| +27.92% | 659B | |
| +27.68% | 557B | |
| -4.59% | 359B | |
| +16.38% | 322B | |
| +9.39% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.58% | 149B |
- Stock Market
- Equities
- FAE Stock
